000538 云南白药
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入20,455,2860.72%39,111,29236,488,37336,373,91932,742,767
减:营业总成本17,225,017-1.36%35,082,75032,087,16831,739,81828,425,125
    其中:营业成本14,462,810-1.70%28,744,51826,883,48526,498,43523,655,878
               财务费用(129,619)22.29%(259,244)(342,878)(258,281)(231,946)
               资产减值损失(3,579)-118.83%(58,128)(664,339)(143,220)(125,480)
公允价值变动收益4,597-91.34%123,566(619,903)(1,929,217)2,240,369
投资收益477,49813.27%779,011868,1981,044,401392,173
    其中:对联营企业和合营企业的投资收益506,63413.33%628,532732,233(21,100)6,308
营业利润3,672,35210.84%4,830,5063,371,2793,485,1696,812,003
利润总额3,672,02811.16%4,818,0123,377,0023,481,6466,801,136
减:所得税费用482,0651.06%695,451536,593683,9861,290,099
净利润3,189,96312.87%4,122,5612,840,4102,797,6615,511,036
减:非控股权益1,133-164.64%28,779(160,716)(7,256)(5,036)
股东净利润3,188,83012.76%4,093,7823,001,1262,804,9175,516,072

市场价值指针
每股收益 (元) *1.79013.29%2.2901.9002.2104.320
每股派息 (元) *----2.0771.5201.6003.900
每股净资产 (元) *22.0652.72%22.19421.42829.80029.789
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容